SecurityPTN / Palatin Technologies, Inc. (696077403)
President and CEOSPANA CARL
IndustryPharmaceutical Preparations
Institutional Owners94
Institutional Shares46,831,684 - 23.18%
Common Shares Outstanding202,048,804 shares (as of 2018-06-30)
Institutional Value$ 48,677,000 USD

Institutional Stock Ownership and Shareholders

PTN / Palatin Technologies, Inc. Institutional Ownership

Palatin Technologies, Inc. (AMEX:PTN) has 94 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 46,831,684 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, Acadian Asset Management Llc, Flynn James E, Renaissance Technologies LLC, State Street Corp, Geode Capital Management, Llc, Northern Trust Corp, Arrowstreet Capital, Limited Partnership, and Ativo Capital Management LLC.
Palatin Technologies, Inc. (AMEX:PTN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-07-27 13F-HR Eqis Capital Management, Inc. 16,229 16
2018-08-14 13F-HR LPL Financial LLC 28,000 31,000 10.71 31 30 -3.23
2018-08-10 13F-HR Legal & General Group Plc 29,244 28
2018-08-14 13F-HR GUGGENHEIM CAPITAL LLC 43,379 0 -100.00 47 0 -100.00
2018-08-14 13F-HR Invesco Ltd. 66,224 64
2018-08-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 546,000 796,000 45.79 595 772 29.75
2018-08-14 13F-HR TWO SIGMA ADVISERS, LP 48,500 59,500 22.68 53 58 9.43
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 0 32,769 0 32
2018-08-14 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 219,795 0 -100.00 240 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 12,157 15,397 26.65 8 8 0.00
2018-09-18 13F-HR/A NORTHERN TRUST CORP 333,277 2,082,532 524.87 363 2,020 456.47
2018-08-14 13F-HR Gotham Asset Management, LLC 45,903 84,784 84.70 50 82 64.00
2018-07-27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 3,406 3
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 173,790 14,338 -91.75 189 14 -92.59
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,361 161,876 6,756.25 3 157 5,133.33
2018-08-14 13F-HR JP Morgan Chase & Co 600 40,436 6,639.33 1 40 3,900.00
2018-08-14 13F-HR MACQUARIE GROUP LTD 1,046,906 405,909 -61.23 1,141 394 -65.47
2018-08-10 13F-HR WASHINGTON TRUST Co 10,000 10,000 0.00 11 10 -9.09
2018-08-03 13F-HR SEI INVESTMENTS CO 18,534 17,000 -8.28 21 16 -23.81
2018-08-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1,200,914 1,370,214 14.10 1,309 1,329 1.53
2018-08-14 13F-HR Cubist Systematic Strategies, LLC 55,096 0 -100.00 60 0 -100.00
2018-08-15 13F-HR JANE STREET GROUP, LLC 17,000 0 -100.00 19 0 -100.00
2018-08-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 300,868 292
2018-08-14 13F-HR UBS Group AG 4,078 26,946 560.77 4 26 550.00
2018-08-08 13F-HR Russell Investments Group, Ltd. 47,220 0 -100.00 51 0 -100.00
2018-08-10 13F-HR GLOBEFLEX CAPITAL L P 217,947 211
2018-08-14 13F-HR MORGAN STANLEY 313 418,657 133,656.23 0 406
2018-08-13 13F-HR Renaissance Technologies LLC 2,745,729 2,993
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 16,946 16
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 6,414 6,220
2018-08-13 13F-HR PROFUND ADVISORS LLC 14,326 14
2018-05-22 13F-HR MEMBERS Trust Co 13,150 13,150 0.00 11 14 27.27
2018-05-15 13F-HR National Asset Management, Inc. 38,000 38,000 0.00 33 42 27.27
2018-08-06 13F-HR RHUMBLINE ADVISERS 172,800 168
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 1,015,697 2,476,391 143.81 1,106 2,401 117.09
2018-08-10 13F-HR Pictet & Cie (Europe) SA 62,000 0 -100.00 68 0 -100.00
2018-08-10 13F-HR CITIGROUP INC 28,179 27
2017-01-13 13F-HR MetLife Securities, Inc 200 0
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 13,250 17,450 31.70 6 12 100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 938,530 1,098,128 17.01 590 555 -5.93
2018-08-14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 300,218 291
2018-08-14 13F-HR TWO SIGMA SECURITIES, LLC 39,524 0 -100.00 43 0 -100.00
2018-08-14 13F-HR CREDIT SUISSE AG/ 0 52,671 0 51
2018-08-14 13F-HR Voya Investment Management LLC 82,615 80
2018-08-14 13F-HR COMPTON CAPITAL MANAGEMENT INC /RI 20,000 10,000 -50.00 22 10 -54.55
2018-08-08 13F-HR AMERICAN INTERNATIONAL GROUP INC 0 127,796 0 124
2018-08-13 13F-HR Ativo Capital Management LLC 1,100,338 1,067
2018-08-06 13F-HR STRS OHIO 769,500 746
2018-07-17 13F-HR WealthTrust-Arizona, LLC 200 200 0.00 0 0
2018-08-14 13F-HR AQR CAPITAL MANAGEMENT LLC 18,079 18
2017-04-07 13F-HR CT Financial Advisors LLC 375 375 0.00 189 123 -34.92
2018-08-14 13F-HR ROYAL BANK OF CANADA 19,042 19,563 2.74 21 19 -9.52
2018-08-14 13F-HR DEUTSCHE BANK AG\ 1,578,404 314,622 -80.07 1,720 304 -82.33
2018-08-13 13F-HR OXFORD ASSET MANAGEMENT 312,050 98,252 -68.51 340 96 -71.76
2018-08-16 13F-HR Carnegie Capital Asset Management, LLC 30,000 30,000 0.00 38 29 -23.68
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 40,996 2,546 -93.79 45 2 -95.56
2018-07-31 13F-HR Destination Wealth Management 5 0
2018-08-14 13F-HR Alyeska Investment Group, L.P. Call 1,538,462 465,732 -69.73 1,677 452 -73.05
2018-08-14 13F-HR TEACHERS ADVISORS INC 253,625 246
2018-07-30 13F-HR WealthTrust Axiom LLC 22,060 21,650 -1.86 24 20 -16.67
2018-08-01 13F-HR FIRST MANHATTAN CO 50 50 0.00 0 0
2018-08-14 13F-HR BlueCrest Capital Management Ltd 23,260 0 -100.00 25 0 -100.00
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 109,795 58,069 -47.11 69 56 -18.84
2018-08-16 13F-HR M Holdings Securities, Inc. 12,289 0 -100.00 13 0 -100.00
2018-08-14 13F-HR Crestwood Advisors LLC 25,000 25,000 0.00 27 23 -14.81
2018-07-11 13F-HR Cordasco Financial Network 2,940 2,940 0.00 3 3 0.00
2018-08-13 13F-HR Certified Advisory Corp 500 500 0.00 0 1
2018-08-14 13F-HR PANAGORA ASSET MANAGEMENT INC 49,853 83,301 67.09 54 81 50.00
2018-08-14 13F-HR FLAGSHIP HARBOR ADVISORS, LLC 8,000 7
2018-08-13 13F-HR PRUDENTIAL FINANCIAL INC 11,970 12
2018-08-13 13F-HR PRINCIPAL FINANCIAL GROUP INC 64,505 62
2018-07-18 13F-HR AMALGAMATED BANK 29,092 28
2018-08-07 13F-HR SG Americas Securities, LLC 71,541 69
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 488,202 488,202 0.00 532 473 -11.09
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 0 89,520 0 87
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,080 1,080 0.00 1 1 0.00
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 246,887 0 -100.00 269 0 -100.00
2018-08-14 13F-HR STATE STREET CORP 68,539 2,679,255 3,809.10 75 2,596 3,361.33
2018-08-02 13F-HR Adviser Investments LLC 24,028 23
2018-08-14 13F-HR BARCLAYS PLC 128,400 207,165 61.34 140 201 43.57
2018-07-17 13F-HR Baystate Wealth Management LLC 13,233 13,233 0.00 16 13 -18.75
2018-08-13 13F-HR ALLIANCEBERNSTEIN L.P. 39,600 38
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 582,644 79,923 -86.28 635 78 -87.72
2018-08-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 118,200 115
2018-08-14 13F-HR FIFTH THIRD BANCORP 10,000 10,000 0.00 11 10 -9.09
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 14,815 17,815 20.25 16 17 6.25
2018-07-31 13F-HR Commonwealth Equity Services, Llc. 21,880 20,500 -6.31 23 20 -13.04
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 172,183 202,850 17.81 188 197 4.79
2017-02-10 13F-HR BlackRock Advisors LLC 23,498 23,498 0.00 15 12 -20.00
2018-08-08 13F-HR US BANCORP \DE\ 159,740 159,740 0.00 174 155 -10.92
2018-05-17 13F-HR McKinley Carter Wealth Services, Inc. 500 1
2018-08-14 13F-HR VANGUARD GROUP INC 7,581,555 8,863,159 16.90 8,264 8,595 4.01
2017-02-14 SC 13G/A Flynn James E 4,733,815 2,967,391 -37.32
2018-08-10 13F-HR Cambridge Investment Research Advisors, Inc. 12,090 12
2018-08-09 13F-HR BlackRock Inc. 1,224,984 10,669,330 770.98 1,335 10,348 675.13
2018-08-13 13F-HR Advisor Group, Inc. 2,765 2,765 0.00 3 3 0.00
2018-08-13 13F-HR AJO, LP 1,242,316 0 -100.00 1,354 0 -100.00
2018-08-10 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 23,498 23,498 0.00 26 23 -11.54
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 3,315,152 3,246,810 -2.06 3,613 3,149 -12.84
2018-07-30 13F-HR/A Virtu Financial LLC 153,354 0 -100.00 167 0 -100.00
2018-08-15 13F-HR SALEM INVESTMENT COUNSELORS INC 0 150 0 0
2018-02-15 13F-HR Bb&t Investment Services, Inc. 20 20 0.00 0 0
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 365,200 355
2018-08-13 13F-HR PALISADE CAPITAL MANAGEMENT LLC/NJ 19,010 19,010 0.00 21 19 -9.52
2018-08-13 13F-HR AMP Capital Investors Ltd 75,300 73
2018-08-10 13F-HR Tibra Equities Europe Ltd 387,535 0 -100.00 422 0 -100.00
2018-08-13 13F-HR ProShare Advisors LLC 25,840 25
PTN : Palatin Technologies Stock Analysis and Research Report

2017-10-26 - Asif

Palatin Technologie is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (“HSDD”), which is a type of female sexual dysfunction (“FSD”), defined as low desire with associated distress. In addition, Palatin has drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The following drug development programs are actively under development: Bremelanotide, an as-needed subcutaneous injectable product for the treatment of HSDD in premenopausal women. Bremelanotide is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulat...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2018 Results - Earnings Call Transcript

2018-09-13 seekingalpha
Good morning, ladies and gentlemen, and welcome to the Palatin Technologies Fourth Quarter and Fiscal Year End 2018 Operating Results Conference Call. As a reminder, this conference is being recorded. (32-0)

AMAG Pharmaceuticals: A Well-Positioned Player In The Pharmaceutical Space

2018-08-27 seekingalpha
Bremelanotide - AMAG's new product - withholds blockbuster potential to fulfill women's need in a billion-dollar market. (32-6)

The Women’s Libido Pill Is Back, and So Is the Controversy - Bloomberg

2018-06-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (76-11)

Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors. (299-6)

Palatin shares surge 9% premarket after FDA accepts for review treatment for HSDD - MarketWatch

2018-06-04 marketwatch
Palatin Technologies Inc. shares PTN, +7.21% surged 9% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has accepted the new drug application for bremelanotide, a treatment for female sexual desire disorder. The NDA was filed by Amag Pharmaceuticals Inc. AMAG, +0.61% Palatin's exclusive North America licensee, in March. The goal date for completion of the review is March 23, 2019. (59-0)

Palatin Technologies' (PTN) CEO Carl Spana on Q3 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Good morning, ladies and gentlemen, and welcome to the Palatin Technologies Third Quarter Fiscal Year 2018 Results Conference Call. As a reminder, this conference is being recorded. (59-1)

BRIEF-Palatin Technologies Says Entered Into An Equity Distribution Agreement

2018-04-20 reuters
* PALATIN TECHNOLOGIES INC - CO MAY SELL SHARES OF STOCK, PAR VALUE $0.01 PER SHARE, HAVING AN OFFERING PRICE OF UP TO $25 MILLION Source : bit.ly/2HDue9S Further company coverage: ([email protected]) (48-17)

REFILE-BRIEF-Palatin Technologies Presents Preclinical Data On Investigational Treatment For IBD

2018-04-03 reuters
* PALATIN TECHNOLOGIES PRESENTS PRECLINICAL ORAL FORMULATION DATA ON PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST FOR INFLAMMATORY BOWEL DISEASES (48-4)

CUSIP: 696077403